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Hereditary systemic amyloidosis associated with a new apolipo- and is associated with a structurally altered protein that
protein AII stop codon mutation Stop78Arg. aggregates to form amyloid fibrils. These proteins may
Background. Mutations in the gene for apolipoprotein AII be the result of single nucleotide change, deletion, or
(apoAII) have recently been found to cause hereditary renal insertion in the gene coding for the amyloid precursoramyloidosis. In each case amyloid deposition has been associ-
protein [6].ated with a peptide extension at the carboxyl-terminus of apo-
ApoAII is one of the major components of plasmaAII, the result of mutations in the normal stop codon.
Methods. A Caucasian man who has had progressive renal high-density lipoprotein (HDL) and is mainly produced
dysfunction since age of 34 was found to have amyloidosis on renal in the liver and small intestine with N-terminus pre- and
biopsy at age 56. Echocardiogram showed mild intraventricular propeptides. Mature apoAII is composed of 77 amino
septal thickness and technetium-99m (99mTc)-pyrophosphate scin- acid residues and, in plasma, exists mainly as a disulfide-tigraphy demonstrated uptake by cardiac muscle consistent with
linked dimer with molecular weight of approximately 17amyloid deposition in the myocardium. His father died of renal
kD [7]. Although previously apoAII was known to formfailure and his paternal half brother has renal dysfunction.
Results. DNA sequencing of the apoAII gene in the proband amyloid fibrils only in the senescence accelerated mouse
showed a T to C transition at the first position of the stop (SAM) model of aging [8], recently Benson et al [5]
codon indicating replacement of the stop codon by l-arginine identified a novel type of amyloid composed of a variant
(Arg) at residue 78. Western analysis of the proband’s plasma apoAII isolated from kidney of an autopsied patient inunder reducing conditions using anti-apoAII revealed an extra
a kindred originally reported in 1973 [9]. Of particularband at approximately 10 kD in addition to the normal apoAII
interest, the patient’s renal amyloidosis was associatedband at 8 kD. Western analysis of solubilized amyloid fibrils iso-
with a stop codon mutation of apoAII (Stop78Gly), in-lated from rectal biopsy tissue contained only the variant apoAII.
Conclusion. These results indicate that the proband’s amy- ducing a variant apoAII consisting of a 77 amino acid
loid fibrils are derived from apoAII and the amyloidogenesis mature apoAII protein plus a carboxyl (C)-terminal pep-
is linked to the peptide extension at the carboxyl-terminus of tide elongation [5]. Additionally, a subsequent study
variant apoAII. Of particular interest is that this novel apoAII
demonstrated a patient with renal amyloidosis associatedvariant may cause amyloid cardiomyopathy in addition to renal
with a different apoAII stop codon mutation (Stop78Ser)amyloid.
[10]. As expected, the patient also had a variant apoAII
with a C-terminal peptide extension, consistent with that
seen in patients described by Benson et al [5], exceptHereditary nonneuropathic renal amyloidosis, as orig-
for one amino acid, Ser instead of Gly at residue 78inally described by Ostertag [1], may be caused by muta-
[10]. Hence, it was hypothesized that human apoAIItions in a number of plasma proteins, including apolipo-
amyloidosis might be linked to the peptide extension atprotein AI (apoAI), fibrinogen A-chain, lysozyme, and
the C-terminus of variant apoAII.apolipoprotein AII (apoAII) [2–5]. Each type of amy-
In this paper, we report a kindred in which renal amy-loidosis is inherited as an autosomal-dominant disease
loidosis is associated with a novel stop codon mutation
of apoAII.
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States at age 49 years. He had been well until he was
found to have proteinuria and hypertension at age 34
years. While his serum creatinine (normal 1.5 mg/dL)
level was 1.8 mg/dL at the age of 36 years, no extensive
medical studies were done at that time. His renal function
gradually worsened and at age 50 years he was found to
have a serum creatinine level as high as 2.2 mg/dL and
3 g of daily proteinuria. An electrocardiogram (ECG)
suggested a previous myocardial infarction but coronary
angiography revealed no significant disease. By age 54
years, his serum creatinine was elevated to 3.0 mg/dL
and blood urea nitrogen (BUN) (normal 25 mg/dL)
level was 40 mg/dL. Physical examination at age 56 years
showed that his arterial blood pressure was 150/80. There
were no signs of hepatosplenomegaly or polyneuropathy.
Laboratory examinations revealed mild normocytic ane-
mia [red blood cell count 4.21  106/mm3 (normal 4.5 to
6.0  106/mm3) and hemoglobin 12.6 g/dL (normal 14 to
18 g/dL)] with weekly erythropoietin injections. Serum
levels of creatinine and BUN were elevated to 3.5 mg/dL
and 51 mg/dL, respectively. Plasma lipid profile revealed
cholesterol 227 mg/dL, HDL cholesterol 55 mg/dL, triglyc-
erides 170 mg/dL, very low-density lipoprotein (VLDL)
34 mg/dL, and low-density lipoprotein (LDL) 138 mg/dL.
There was no evidence of monoclonal gammopathy on
immunofixation of serum or urine. An ECG disclosed
poor R progression in leads V1 to V3, and echocardiogra-
phy showed mild intraventricular septal thickness (1.5
cm, normal range1.2 cm). Ventricular wall motion was Fig. 1. Renal biopsy. (A ) Extensive glomerular amyloid deposits and
intact. Ejection fraction was estimated at 60%. Stress amyloid in walls of blood vessels. (B ) Congo red staining.
ECG showed no ischemic changes. Technetium-99m
(99mTc)-pyrophosphate scintigraphy showed slight uptake
by cardiac muscle consistent with amyloid deposition.
DNA isolationAbdominal ultrasound examination showed no abnor-
After full informed consent was obtained, genomicmality of liver or spleen. Renal scintigraphy demonstrated
DNA of the proband was isolated from peripheral bloodmoderately decreased flow and function of kidneys, with
leukocytes using standard phenol/chloroform method.total glomerular filtration rate (GFR) to be 19.7 mL/min.
DNAs of other family members were not available forRenal biopsy performed at age 55 years revealed evi-
investigation.dence of focal glomerulosclerosis in addition to amyloid
deposition in glomeruli and vascular walls (Fig. 1). A Single-strand conformation polymorphism (SSCP) analysis
skin biopsy revealed amyloid deposition in vascular walls
Exons 3 and 4 of apoAII gene were examined by single-
in the dermis. Abdominal fat pad aspiration was negative strand conformation polymorphism (SSCP) analysis us-
for amyloid deposition. Bone marrow biopsy demon- ing oligonucleotide primers described elsewhere [5].
strated no abnormality and no amyloid deposition. Rec- Polymerase chain reaction (PCR) was done in a total
tal biopsy revealed amyloid deposition in vascular walls volume of 50 L, containing 5 L of 10  PCR buffer
in the submucosa. DNA analysis of a number of genes (100 mmol/L Tris HCl, pH 8.3, 500 mmol/L KCl, and 12
that are associated with renal amyloidosis, including apoAI, mmol/L MgCl2), 8 L of 1.25 mmol/L desoxynucleoside
fibrinogen A-chain, and lysozyme, failed to reveal any triphosphate (dNTP), 15 pmol of each primer, 2.5 units
abnormalities. of Taq polymerase (Sigma Chemical Co., St. Louis, MO,
The proband’s father died of renal insufficiency at 53 USA), and 100 ng of genomic DNA. Amplification was
years of age. A paternal half brother (age 45 years) has performed using a Perkin-Elmer ThermalCycler (Nor-
suffered from renal failure. The proband has a 21-year- walk, CT, USA) for 40 cycles consisting of denaturing
at 95C for 30 seconds, annealing at 63C (exon 3) orold son who is in good health.
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60C (exon 4) for 1 minute, and extension at 72C for
30 seconds. SSCP analysis was done as described pre-
viously [10].
Direct DNA sequence analysis
DNA was analyzed by direct sequencing of exons 3
and 4 of the apoAII gene. PCR was done as indicated
above. The PCR product was purified by QIAquick PCR
Purification kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s protocol. Sequencing reaction was
performed by using 1.0 L of purified PCR product as
template and the Thermo Sequence [-33P]-ddNTP–radio-
labeled terminator cycle sequencing kit (USB; Cleve-
land, OH, USA). Samples were electrophoresed on a 6%
polyacrylamide gel at 45 W for 3 hours using a glycerol-
Fig. 2. DNA sequence analysis of exon 4 of apolipoprotein AII
tolerant gel buffer, dried, and exposed to Kodak X-Omat (apoAII) gene. Both T and C are present at the first position of apoAII
stop codon (arrow) in the DNA sequence of the patient, indicating afilm (Rochester, NY, USA).
replacement of stop codon by arginine (Arg) at codon 78. Abbreviations
are: Ser, serine; Gln, glycine; Thr, threonine; Ala, alanine.Western analysis of plasma
Plasma samples were heated in a boiling water bath
for 10 minutes with or without 5% 2-mercaptoethanol
gene (TGA to CGA) indicating a stop to arginine substi-(2-ME) and electrophoresed on a 16.5% Tris-Tricine
tution at codon 78 followed by 60 bases before a newReady gel (Bio-Rad, Hercules, CA, USA). Subsequently,
stop codon (Figs. 2 and 3) [12]. No other mutations wereproteins were electrotransferred onto nitrocellulose mem-
found in exons 3 and 4 of apoAII gene, which encodebrane (Trans-Blot Transfer Medium; Bio-Rad). After
the entire pro- and mature apoAII protein [12].blocking the membrane with 5% nonfat dry milk in phos-
To exclude the possibility that the T to C mutationphate-buffered saline (PBS), pH 7.4, the apoAII bands
might be a polymorphism, we analyzed DNA from 50were detected with sheep anti-human apoAII (Roche,
unrelated individuals (100 alleles) by SSCP analysis.Indianapolis, IN, USA). Alkaline phosphatase conju-
None had the abnormal SSCP pattern as seen in thegated donkey anti-sheep IgG (Sigma Chemical Co.) was
patient (data not shown).used as the second antibody. The immunoblots were visu-
alized with a reaction to nitro blue tetrazolium/bromo-
Characterization of plasma apoAII4-chloro-3-indolyl phosphate (NBT/BCIP) alkaline phos-
phatase substrate (Sigma Chemical Co.). Plasma samples, obtained from this patient, patients with
variant apoAII proteins described previously (apoAIIRectal biopsy tissue was hand homogenized in PBS,
centrifuged, and washed twice by resuspension in PBS Stop78Gly and Stop78Ser mutations) [5, 10], and a normal
individual, were studied by Western analysis using anti-followed by centrifugation at 14,000 rpm  15 minutes
[11]. The pellet was dialyzed against distilled water and human apoAII (Fig. 4). In the patient in this study, posi-
tive bands migrating with molecular weight correspond-lyophilized. Freeze-dried material was dissolved in 6
mol/L guanidine containing dithiothreitol, alkylated with ing to dimeric normal apoAII, heterodimeric apoAII
with normal and variant molecules, and dimeric variantiodoacetic acid, dialyzed versus water and lyophilized.
Western analysis was performed as noted above for apoAII were identified in nonreducing conditions. In the
presence of 2-ME, Western analysis revealed two bandsplasma samples.
(approximately 8 and 10 kD) corresponding to normal
apoAII monomer and the larger variant apoAII mono-
RESULTS mer, respectively. The molecular weight of the variant
DNA analysis apoAII in the patient described here was the same as in
patients previously reported [5, 10].SSCP analysis revealed an abnormally migrating band
for apoAII exon 4 PCR products of the patient in con-
Characterization of isolated amyloid fibril proteintrast to those of normal controls, which was different
from those in patients with apoAII Stop78Gly mutation Western analysis using anti-apoAII of amyloid fibril
protein isolated from rectal biopsy tissue identified a[5] and Stop78Ser mutation [10] (data not shown). Direct
DNA sequencing of the exon 4 PCR product showed a protein band migrating at the same level as the variant
apoAII in serum. No apoAII band corresponding tosingle-base substitution in the stop codon for the apoAII
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Fig. 3. Schema of 3 cDNA sequence and de-
duced C-terminal amino acid sequence in the
patient shows that the Stop78Arg mutation
induces an extended peptide composed of 21
amino acids.
Fig. 4. Western blot of patient’s plasma with anti-human apolipopro-
tein AII (apoAII). Nonreduced denatured and reduced denatured
plasma samples were run in lanes C (normal control), G78 (a patient
with apoAII Stop78Gly variant [5]), S78 (a patient with apoAII
Stop78Ser variant [10]), and R78 (the patient in this study). Abbrevia-
tions are: N, normal apoAII monomeric form; V, variant apoAII mono-
meric form; V  V, N  V, and N  N, dimeric forms of apoAII.
Fig. 6. Schema of three identified mutant apolipoprotein AII (apoAII)
amyloid proteins compared to wild-type apoAII. Each variant is a 98
residue protein differing only at residue 78.
DISCUSSION
Human apoAII amyloidosis is now known as one form
of hereditary renal and nonneuropathic amyloidosis,
similar to that described by Ostertag [1]. Previously two
different mutations were identified and, surprisingly,
both mutations were located in the stop codon of apoAII
(Stop78Gly and Stop78Ser) and induce a C-terminal 21
amino acid extension (Fig. 6) [5, 10]. Clinically, the most
prominent manifestation in all affected patients of both
Fig. 5. Western analysis of serum and amyloid fibrils from patient with families was renal failure due to amyloid deposition in
apolipoprotein AII (apoAII) amyloidosis. Serum of the patient (lane 2)
the kidney (Table 1). Symptoms due to amyloidosis ofshows both normal (N) and variant (V) apoAII under reducing condi-
tions, whereas a normal control serum (lane 3) contains only normal other visceral organs, including the heart, liver, spleen,
apoAII. Amyloid fibrils isolated from the patient (lane 1) contain only and peripheral nerves, were absent. The onset of the
the variant apoAII, indicating that either reduction of the disulfide
disease in both families varied from adolescence to thelinked dimer occurs prior to amyloid fibril formation or only the variant
homodimer participates in the amyloid process. fifth decade [9, 10]. While autopsy studies in the first
reported family with apoAII Stop78Gly variant revealed
that amyloid accumulation was present in most visceral
wild-type apoAII was identified in the isolated tissue organs, except for central nervous system and peripheral
preparation indicating that no significant blood contami- nerves, renal amyloid was the most prominent feature
[9]. The severity of amyloid deposition in the liver, heart,nation was present (Fig. 5).
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Table 1. Three families with apoAII mutation
Family 1 2 3
Residence United States United States United States
(Armenian descent)
Mutation Stop78Gly Stop78Ser Stop78Arg
Onset of the disease 2nd–5th decade 5th decade 4th decade
Main clinical manifestation Nephropathy Nephropathy Nephropathy
Cardiomyopathy   
Organs where amyloid deposits were proven Kidney, adrenals, liver, spleen, heart Kidney, bone marrow Kidney, skin, rectum
Reference 5, 9 10 Present study
and spleen was moderate and limited mainly to vascular application of microtechniques for amyloid tissue charac-
terization, as used in this study, has expanded the meanswalls [9]. In the present study, DNA analysis revealed
that the patient was heterozygous for a novel stop codon to correctly analyze the pathology of these diseases [11].
Both Western analysis and amino acid sequence analysismutation in the apoAII gene (TGA to CGA) that causes
replacement of the stop codon by arginine at codon 78. are now feasible methods for determining the type of
amyloid in tissues.Western analysis of the patient’s plasma using anti-hu-
man apoAII revealed not only a normal apoAII but also In addition, although not performed in the present
study, immunohistochemistry using anti-apoAII, whicha variant apoAII. On Western analysis, the molecular
weight of the variant apoAII in this patient was the same is used for Western analysis, may be helpful for diagnosis.
While the precise mechanisms of amyloid fibril forma-as that of patients with apoAII variant Stop78Gly [5]
and Stop78Ser [10]. Therefore, our results suggest that tion in human apoAII amyloidosis, especially how the
apoAII molecule obtains the -sheet configuration dur-the variant apoAII induced by Stop78Arg mutation in
the patient described here consists of a C-terminal 21 ing fibril formation, are not clear, all patients among the
three families had an extended 21 amino acid peptideamino acid extension as well as a normal apoAII, as has
at the C-terminus in common; although the first residuebeen seen in patients reported previously (Fig. 6), since
of that 21 residue peptide (glycine [5], serine [10], orthe Stop78Arg mutation does not cause a frame-shift.
arginine at residue 78) is different in each family (Fig. 6).The most noticeable clinical manifestation of the pa-
To date, there have not been reports of human apoAIItient in this study was nephropathy caused by renal amy-
amyloidosis caused by other mutations except for the stoploidosis, which resembles that in patients with variant
codon site. Therefore, it is likely that the role of humanapoAII reported previously, although the onset of the
apoAII as a precursor of amyloid fibrils is linked to thedisease varied among the three families (Table 1). While
extension of the protein at the C-terminus. This is clearlythe mechanism of how amyloid proteins have organ spec-
different from the SAM model, in which amyloidogenesisificity that leads to variation in clinical features is un-
is linked to difference in the apoAII N-terminal sequenceknown, the nonneuropathic and nephropathic syndrome
[14, 15]. The importance of newly induced C-terminalis the common feature for apoAII amyloidosis. The clini-
peptide in amyloid formation has also been identifiedcal features of apoAII amyloidosis are similar to fibrino-
with fibrinogen Aa-chain [16, 17], ABri in familial Britishgen A-chain and lysozyme amyloidosis in terms of ne-
dementia [18], and ADan in familial Danish dementiaphropathy without neuropathy [3, 4, 13]. However, the
[19]. The new peptide sequence at the C-terminus inlatter forms (fibrinogen A-chain and lysozyme) usually
variant apoAII is predicted to contain an -helix that isshow more extensive hepatic and splenic involvement.
different from the three class A amphipathic helices,On the other hand, in the proband described herein,
important for lipid binding [20]. As suggested previouslyamyloid deposition in the myocardium was suggested by
[5], it is likely that decreased binding capacity to HDL99mTc-pyrophosphate scintigraphy, ECG, and echocardi-
caused by variant apoAII with extended sequence with-ography. As mentioned above, a previous study [9]
out lipid binding capability could alter its metabolismshowed that amyloid deposition in the heart was limited
and accelerate amyloid fibril formation.to only vascular walls. Also, in the patient with variant
apoAII Stop78Ser, there was no clinical evidence of amy-
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